2. Signaling Pathways
  3. Immunology/Inflammation
  4. CD47

CD47

Cluster of Differentiation 47; MER6; OA3

CD47 is a glycoprotein that was first identified in 1990 as a protein that associates with integrins, hence its original name integrin-associated protein. CD47 interacts with SIRPα (CD172a or SHPS-1) and its family member SIRPγ, CD47 also interacts with integrins and secreted glycoprotein extracellular matrix protein thrombospondin-1 (TSP-1). Signaling through the CD47/SIRPα axis plays a role in various homeostatic processes, such as maintenance of erythrocytes, innate immune cells and T cells. Moreover, cancer cells and virus-infected and bacteria-infected cells can upregulate CD47 protein expression to prevent immune-mediated elimination.

CD47 Related Products (59):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P991693
    Ipsoprubart
    		Inhibitor
    Ipsoprubart is a humanized IgG1κ antibody targeting SIRPa/CD172a. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001).
    Ipsoprubart
  • HY-P991560
    TQB-2928
    		Inhibitor
    TQB-2928 is a monoclonal antibody against CD47, which can be used in the study of cancer.
    TQB-2928
  • HY-P3968
    Thrombospondin-1 (1016-1021) (human, bovine, mouse)
    Thrombospondin-1 (1016-1021) (human, bovine, mouse), a Thrombospondin-1-derived peptide, is a truncated peptide devoid of CD47-binding activity.
    Thrombospondin-1 (1016-1021) (human, bovine, mouse)
  • HY-P991927
    ZL-1201
    		Inhibitor
    ZL-1201 is a recombinant humanized monoclonal anti-CD47 IgG4 antibody. ZL-1201 disrupt the CD47-SIRPα interaction. ZL-1201 modulates the tumor microenvironment. ZL-1201 promotes tumor-associated macrophage phagocytic activity. ZL-1201 substantially enhances phagocytosis by M2 macrophages, but not by M1 macrophages. ZL-1201 in combination with both mAb and chemotherapy achieves the maximal antitumor effects in a variety of solid tumor models. ZL-1201 can be used in the study of lymphoma, breast cancer, ovarian cancer, head and neck squamous cell carcinoma, and gastric cancer.
    ZL-1201
  • HY-P11205
    Cys-PKHB1
    		Activator
    Cys-PKHB1 (Cys-txCD47) is a peptide conjugated to PKHB1, a CD47 agonist peptide and a thrombospondin-1 peptide mimic with antitumor effects. PKHB1 induces mitochondrial alterations, ROS generation, intracellular Ca+ accumulation, and calcium-dependent cell death in breast cancer cells. PKHB1 induces immune system activation in breast cancer cells through immunogenic cell death.
    Cys-PKHB1
  • HY-P992320
    BAT-6004
    		Inhibitor
    BAT-6004 is a monoclonal antibody that targets CD47 and is a CD47 inhibitor. BAT-6004 can be used in research on acute myeloid leukemia and diffuse large B-cell lymphoma.
    BAT-6004
  • HY-143224A
    NCGC00138783 free base
    		Inhibitor
    NCGC00138783 free base is a selective inhibitor targeting CD47/SIRPα axis, with an IC50 of 50 µM. NCGC00138783 free base directly blocks the interaction between CD47 and SIRPα axis.
    NCGC00138783 free base
  • HY-P992176
    ADU-1805
    		Inhibitor
    ADU-1805 is a humanized monoclonal IgG2 antibody, a selective, pan-allelic anti-SIRPα antibody, with a Kd value of 11.0 × 10-9 M for hSIRPαV1. ADU-1805 binds to all known hSIRPα alleles. ADU-1805 blocks the SIRPα-CD47 interaction, promotes phagocytosis of cells, and enhances trogocytosis of cells. ADU-1805 can be used in research related to Burkitt lymphoma.
    ADU-1805
  • HY-P991755
    Anti-Rat CD47 Antibody (OX-101)
    		Inhibitor
    Anti-Rat CD47 Antibody (OX-101) reacts with CD47. Anti-Rat CD47 Antibody (OX-101) accelerates hematoma clearance and alleviates hydrocephalus after experimental intraventricular hemorrhage. Recommend Isotype Controls: Mouse IgG1 kappa, Isotype Control (HY-P99977).
    Anti-Rat CD47 Antibody (OX-101)
  • HY-143225
    NCGC00538431
    		Inhibitor
    NCGC00538431 is a potent modulator of SIRPα-CD47.
    NCGC00538431
  • HY-P991923
    Anti-CD47 Antibody (1F80)
    Anti-CD47 Antibody (1F80) is an antibody against human CD47. Recommend Isotype Controls:?Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
    Anti-CD47 Antibody (1F80)
  • HY-P991367
    ES004
    		Inhibitor
    ES004 is a human monoclonal antibody (mAb) targeting SIRPα/CD172a. ES004 enhances macrophage phagocytosis and induces potent T cell responses to promote tumor killing. ES004 can be used in Solid tumours research.
    ES004
  • HY-P992158
    VBI-009
    VBI-009 is a CD47 and B7-H3 (CD276) bispecific antibody. VBI-009 blocks CD47-SIRPα 'don't eat me' signals and restricts activity to CD47+/B7-H3+ cells. VBI-009 induces antibody-dependent cellular phagocytosis (ADCP) and antibody-dependent cellular cytotoxicity (ADCC) in CD47+/B7-H3+ tumor cells. VBI-009 inhibits tumor growth in CD47+/B7-H3+ lung cancer xenograft models. VBI-009 can be used for the research of lung cancer.
    VBI-009
  • HY-P991924
    CO-1
    		Inhibitor
    CO-1 is an IgG4 anti-CD47 antibody. CO-1 not only enhances themacrophage phagocytosis activity but also induces a unique and fast form of programmed celldeath (PCD) in cancer cells directly through ligation of CD47. CO-1 has anticancer activity against hematologic malignancies such as acute lymphoblastic leukemia.
    CO-1
  • HY-P991366
    IBI-397
    		Inhibitor
    IBI-397 is a human monoclonal antibody (mAb) targeting SIRPα/CD172a . IBI-397 promotes human monocyte-derived dendritic cell-mediated T cell proliferation and increases the expression of CD86 and HLA-DR. IBI-397 has antitumor activity in the mouse MDA-MB-231 tumor model. IBI-397 can be used in Myeloma research.
    IBI-397
  • HY-181797
    CL121
    		Inhibitor
    CL121 is a Glutaminyl Cyclase inhibitor with an IC50 of 0.07 μM against human sQC and an IC50 of 0.54 μM against human gQC. CL121 reduces the level of pyroglutamate (pE)-modified CD47 on the surface of cancer cells. CL121 exhibits anti-tumor activity against triple-negative breast cancer.
    CL121
  • HY-P991925
    SHR-1603
    		Inhibitor
    SHR-1603 is a humanized anti-CD47 IgG4 antibody. SHR-1603 blocks the interaction of CD47 with SIRPα and enhances phagocytosis. SHR-1603 includes active Fc domains to mediate CDC/ADCC functions. SHR-1603 can be used for the research of cancer[1][2].
    SHR-1603
  • HY-P10371
    PKHB1
    		Agonist
    PKHB1 (txCD47) is a CD47 agonist and Thrombospondin-1 peptide mimetic. PKHB1 activates CD47 and triggers Caspase-independent, calcium-dependent cell death via mitochondrial alterations, ROS production, endoplasmic reticulum morphological changes, and dissipation of mitochondrial membrane potential. PKHB1 induces the exposure of Calreticulin, HSP70, and HSP90, thereby driving immunogenic cell death. PKHB1 promotes intratumoral CD8+ T cell infiltration and inhibits breast tumorigenesis. PKHB1 reduces HSV-1 levels and alleviates the severity of herpes simplex keratitis. PKHB1 can be used in research related to breast cancer, herpes simplex keratitis, and T-cell acute lymphoblastic leukemia.
    PKHB1
  • HY-P991561
    AO-176
    		Inhibitor
    AO-176 is a humanized anti-CD47 IgG2 monoclonal antibody. AO-176 induces tumor phagocytosis through blocking the CD47-SIRPα interaction. AO-176 preferentially binds to tumor versus normal cells and directly kills tumor by a cell autonomous mechanism not ADCC (antibody-dependent cell-mediated cytotoxicity). AO-176 demonstrates dose-dependent antitumor activity in tumor xenograft models. AO-176 can be used for the researches of cancer, such as lymphoma.
    AO-176